Financial Statements March 31, 2017



August 16, 2017

Independent Auditor's Report

To the Board of Directors of The Terry Fox Research Institute

We have audited the accompanying financial statements of The Terry Fox Research Institute, which comprise the statement of financial position as at March 31, 2017 and the statements of operations, changes in net assets and cash flows for the year then ended, and the related notes, which comprise a summary of significant accounting policies and other explanatory information.

Management's responsibility for the financial statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Canadian generally accepted auditing standards. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified audit opinion.



Opinion

In our opinion, the financial statements present fairly, in all material respects, the financial position of The Terry Fox Research Institute as at March 31, 2017 and the results of its operations and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

Chartered Professional Accountants

Pricewaterhouse Coopers LLP

Statement of Financial Position As at March 31, 2017

	2017 \$	2016 \$
Assets	•	4
Current assets Cash Accounts receivable and other assets Due from The Terry Fox Foundation (note 6)	127,576 56,477 569,491	2,270,340 98,800 20,965
	753,544	2,390,105
Capital assets (note 3)	4,306	9,076
	757,850	2,399,181
Liabilities		
Current liabilities Accounts payable and accrued liabilities Grants payable (note 7(c))	80,968 322,711	72,266 2,000,000
	403,679	2,072,266
Pension obligation (note 4)	269,155	236,379
	672,834	2,308,645
Net assets		
Invested in capital assets	4,306	9,076
Unrestricted	80,710	81,460
	85,016	90,536
	757,850	2,399,181
Commitments (note 7)		

Approved by the Board of Directors

Director

Director

Statement of Operations

For the year ended March 31, 2017

	2017 \$	2016 \$
Revenue Research funding The Terry Fox Foundation (note 6) Other research funding Other income	22,344,236 361,685 1,251	23,126,582 671,265 101
	22,707,172	23,797,948
Research expenses Translational cancer research programs Discovery programs Program project grants New investigator awards Cancer centre pilots Research training and other Program development and delivery costs	4,933,655 14,537,862 1,344,009 - 178,333 486,695	4,676,830 13,137,664 1,531,484 2,017,078 409,389 518,250
	21,480,554	22,290,695
Administrative expenses (note 5)	1,232,138	1,290,459
	22,712,692	23,581,154
(Deficiency) excess of revenue over expenses	(5,520)	216,794

Statement of Changes in Net Assets

For the year ended March 31, 2017

			2017	2016
	Invested in capital assets \$	Unrestricted \$	Total \$	Total
Balance - Beginning of year	9,076	81,460	90,536	(126,258)
(Deficiency) excess of revenue over expenses	(4,770)	(750)	(5,520)	216,794
Balance - End of year	4,306	80,710	85,016	90,536

Statement of Cash Flows

For the year ended March 31, 2017

	2017 \$	2016 \$
Cash provided by (used in)		
Cash flows from operating activities (Deficiency) excess of revenue over expenses Item not affecting cash - amortization	(5,520) 4,770	216,794 4,385
Changes in non-cash operating working capital Accounts receivable and other assets Accounts payable and accrued liabilities Grants payable Due from The Terry Fox Foundation	(750) 42,323 8,702 (1,677,289) (548,526)	221,179 (41,173) (15,060) 2,000,000 (68,556)
Cash flows from financing activities Increase in pension plan liability Decrease in deferred contributions	(2,175,540) 32,776 - 32,776	2,096,390 30,675 (26,250) 4,425
Cash flows from investing activities Purchase of capital assets		(6,918)
(Decrease) increase in cash	(2,142,764)	2,093,897
Cash - Beginning of year	2,270,340	176,443
Cash - End of year	127,576	2,270,340

Notes to Financial Statements March 31, 2017

1 General

The Terry Fox Research Institute (the "Institute") is a registered charity and was incorporated by letters patent on March 14, 2007 to promote, advance and fund scientific research into the diagnosis, treatment and prevention of cancer. The Institute's mission is to provide grants to groups of researchers working toward a common goal based on excellence and the potential for impact.

The Terry Fox Foundation (the "Foundation"), a party related to the Institute, raises funds for cancer research. Funds raised are provided to the Institute for allocation to the best cancer research. The Institute and the Foundation are maintained as separate and independent organizations with many common purposes and mutual interests. Certain services are shared between the Institute and the Foundation in order to reduce costs and increase efficiencies.

2 Significant accounting policies

These financial statements are prepared in accordance with Canadian accounting standards for not-for-profit organizations in Part III of the Chartered Professional Accountants of Canada ("CPA Canada") Handbook - Accounting. The Institute's significant accounting policies are as follows:

Revenue recognition

The Institute follows the deferral method of accounting for contributions which include donations and government grants.

Unrestricted contributions are recognized as revenue when received or receivable if the amount to be received can be reasonably estimated and collection is reasonably assured.

Externally restricted contributions are recognized as revenue in the year in which the related expenses are recognized.

Interest income on short-term investments is recorded on an accrual basis.

Research and other expenses

Research includes research funding and the costs of managing research programs. Research funding (for translational and discovery projects, research centres and training) focuses on activities to advance our understanding, diagnosis and treatment of cancer with the goal of improving significantly the outcomes of cancer research for the patient. Managing research programs focuses on activities such as the scientific review process, research forums, advisory committees and linkage with researchers.

The Institute recognizes a research grant expense when an approved research recipient has complied with the conditions of a research grant or collaborative research agreement and the Institute has approved payment of the research grant expense.

Other operating expenses are recognized on the accrual basis of accounting.

Notes to Financial Statements March 31, 2017

Financial instruments

Financial instruments are recorded at fair value on initial recognition and subsequently recorded at cost or amortized cost, unless management has elected to carry the instruments at fair value. The Institute has not elected to carry any such financial instruments at fair value.

Transaction costs incurred on the acquisition of financial instruments measured subsequently at fair value are expensed as incurred. All other financial instruments are adjusted by transaction costs incurred on acquisition and financing costs, which are amortized using the straight-line method.

Capital assets

Capital assets are stated at cost, less accumulated amortization. Amortization is provided using the straight-line method and following annual rates:

Leasehold improvements	5 years
Computer equipment	3 years
Furniture and office equipment	5 years

Use of estimates

These financial statements have been prepared in accordance with Canadian accounting standards for not-forprofit organizations which require management estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

3 Capital assets

			2017	2016
	Cost \$	Accumulated amortization \$	Net \$	Net \$
Furniture and office equipment	1,021	1,021	-	-
Computer equipment	39,971	35,665	4,306	9,076
Leasehold improvements	29,960	29,960	<u> </u>	<u> </u>
	70,952	66,646	4,306	9,076

4 Pension obligation

The Institute has a defined contribution supplemental pension arrangement for one of its senior management employees. The liabilities accrue annually and will be payable by the Institute upon the employee's retirement. The benefits are based on years of service and annual base salary as determined by the Institute. The obligation is \$269,155 (2016 - \$236,379).

Notes to Financial Statements March 31, 2017

5 Administrative expenses

	2017 \$	2016 \$
Amortization	4,770	4,385
General office	37,311	35,576
Governance	15,582	14,565
Legal and professional	8,563	13,059
Office space	59,083	59,083
Partnerships	5,064	892
Program development	15,572	57,220
Research communications	46,477	70,712
Research support services	64,628	35,450
Salaries and benefits	904,181	951,068
Staff Travel	70,907	48,449
	1,232,138	1,290,459

6 Related party transactions

During the year, the Foundation provided the Institute with \$22,344,236 (2016 - \$23,126,582) in research funding. The Institute then distributed \$20,710,041 (2016 - \$21,220,121) of the total funds received to various institutions for cancer research. The remaining funds were used for administrative expenses. The Institute is economically dependent on the Foundation for future research funding.

The Foundation provides the Institute with certain administrative support including finance and payroll. These transactions are in the normal course of operations and are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties.

7 Commitments

- a) The Institute has entered into a lease agreement for office premises that require monthly base rent payments of \$3,030 until June 2018 with a further option to renew.
- b) The Institute has committed to funding research projects on behalf of and based upon suitable support from the Foundation, subject to the availability of funds, over the next five years as follows:

	Cancer research programs \$	Discovery program project grants \$	New investigation awards \$	Cancer centre pilots \$	Research training \$	Total supported by the Foundation \$	Supported by others
2018	6,538,606	13,143,381	1,465,119	1,000,000	220,621	22,367,727	279,399
2019	4,293,119	11,294,715	1,049,425	1,000,000	106,550	17,743,809	125,000
2020	3,673,066	5,641,087	637,465	· · · -	12,829	9,964,447	125,000
2021	3,179,347	3,000,000	· -	-	· -	6,179,347	· -
2022	920,590	750,000	-	=	-	1,670,590	-
	18,604,728	33,829,183	3,152,009	2,000,000	340,000	57,925,920	529,399

Notes to Financial Statements March 31, 2017

c) From time to time, the Institute commits research funds to other organizations in support of a variety of research initiatives that include a requirement that matching or leveraged funds must also be provided by those organizations or other third parties. In the prior year, the Institute expensed \$2.0M towards two Cancer Centre pilot programs to be established at the BC Cancer Agency and the Princess Margaret Hospital. Matching funds for this initiative will be provided directly by those organizations.

8 Risk management

Credit risk

Credit risk refers to the risk that a counterparty may default on its contractual obligations resulting in a financial loss. The Institute deals with creditworthy counterparties to mitigate the risk of financial loss from defaults. The Institute is not exposed to significant credit risk.

Liquidity risk

Liquidity risk is the risk that the Institute will be unable to fulfill its obligations on a timely basis or at a reasonable cost. The Institute manages its liquidity risk by monitoring its operating requirements. The Institute prepares budget and cash forecasts to ensure it has sufficient funds to fulfill its obligations. There has been no change to the risk exposures from 2016.